Acrobiosystems Co

Acrobiosystems Co Pre-Tax Margin

The Pre-Tax Profit Margin of Acrobiosystems Co (301080.SZ) as of Oct 22, 2026 is 20.20 %. In the previous year, Pre-Tax Profit Margin was 19.37 % — a change of 4.32% (higher).

Pre-Tax Margin

20.20 %

YoY

4.32%

Last updated:

Pre-Tax Profit Margin of Acrobiosystems Co is 2025 20.20 % . Pre-Tax Profit Margin of Acrobiosystems Co was 2024 19.37 % . It decreases by 4.32% higher compared to the previous year.

The Acrobiosystems Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
17.20 CNY
Jan 1, 2019
12.22 CNY
Jan 1, 2020
54.25 CNY
Jan 1, 2021
50.77 CNY
Jan 1, 2022
45.31 CNY
Jan 1, 2023
29.55 CNY
Jan 1, 2024
19.37 CNY
Jan 1, 2025
20.20 CNY
The Acrobiosystems Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
20.20 %+4.32%
19.37 %-34.47%
29.55 %-34.78%
45.31 %-10.74%
50.77 %-6.42%
54.25 %+343.83%
12.22 %-28.92%
17.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Pre-Tax Profit Margin of Acrobiosystems Co is 20.20 % in 2025.

Pre-Tax Profit Margin of Acrobiosystems Co changed from 19.37 % to 20.20 %, representing a 4.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co